RNA-targeting therapeutics hold promise for accessing traditionally undruggable proteins, but conventional methods fall short in chemical space coverage. X-Chem’s patent-pending mirror-image RNA-targeted DEL screening breaks these barriers, offering broad chemical diversity, increased signal to noise ratio for hit identification, and a powerful new path to RNA drug discovery.